Full Text
Cost-Effectiveness Analysis For The Treatmet with Daclatasvir-Asunaprevir in Patients Naive with Chronic Hepatitis C Genotype 1b Without Baseline Ns5a Polymorphisms Under The Public Payer Perspective in Mexico

Abstract

Authors

C Gama JM Benita J Celaya

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×